Follicular Lymphoma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for follicular lymphoma. 12 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
12
Active US patents
54/100
Avg vulnerability
$5.8B
Annual revenue covered

Originators in Follicular Lymphoma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Bristol-Myers Squibb 12 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating follicular lymphoma. Each bar = one year. Y-axis scaled to peak year (6 patents).

6
27
6
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Revlimid
lenalidomide
 Bristol-Myers Squibb 12 54 $5.8B 2027-04-27

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
7465800 Revlimid composition of matter 27 2027-04-27
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08
8741929 Revlimid method of use 80 2028-03-08

Related